Market OpportunitiesIbsrela and Xphozah continue to build momentum in large market opportunities with no second-line competition, supporting a clear path to returned profitability.
Revenue GrowthSequential topline growth for Ibsrela is continuing at a fast pace, making management's revenue guidance look conservative.
Sales Force ImpactIbsrela's continued robust growth trajectory with expanded sales force impact is starting to materialize, leading management to guide 2025 net sales of $240-250M, which is considered very achievable.